BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20385980)

  • 1. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
    Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
    Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
    Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
    J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
    Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
    J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
    von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
    J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
    Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
    Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
    Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
    Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
    Eckardt JR; Bentsion DL; Lipatov ON; Polyakov IS; Mackintosh FR; Karlin DA; Baker GS; Breitz HB
    J Clin Oncol; 2009 Apr; 27(12):2046-51. PubMed ID: 19289620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
    O'Brien ME; Konopa K; Lorigan P; Bosquee L; Marshall E; Bustin F; Margerit S; Fink C; Stigt JA; Dingemans AM; Hasan B; Van Meerbeeck J; Baas P
    Eur J Cancer; 2011 Oct; 47(15):2322-30. PubMed ID: 21684151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
    Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
    Nitta T; Yamasaki M; Kajihara T; Mito A; Awaya H; Ikegami Y; Arita K
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1045-9. PubMed ID: 20567105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.
    Schmittel A; Knödler M; Hortig P; Schulze K; Thiel E; Keilholz U
    Lung Cancer; 2007 Jan; 55(1):109-13. PubMed ID: 17097191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
    Igawa S; Otani S; Ryuge S; Fukui T; Nakahara Y; Hiyoshi Y; Ishihara M; Kusuhara S; Harada S; Mitsufuji H; Kubota M; Sasaki J; Masuda N
    Invest New Drugs; 2017 Oct; 35(5):642-648. PubMed ID: 28631097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu CQ; Tian D; Wang N; Meng XP; Yang JD; Li HW; Zhao N; Zhao S; Liao F; Cui Y
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e81-e87. PubMed ID: 29071806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.